0000950170-23-012088.txt : 20230406 0000950170-23-012088.hdr.sgml : 20230406 20230406163108 ACCESSION NUMBER: 0000950170-23-012088 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230331 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20230406 DATE AS OF CHANGE: 20230406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tracon Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001394319 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 342037594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36818 FILM NUMBER: 23806575 BUSINESS ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 BUSINESS PHONE: 858-550-0780 MAIL ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Tracon Pharmaceuticals Inc DATE OF NAME CHANGE: 20070324 8-K 1 tcon-20230331.htm 8-K 8-K
0001394319false00013943192023-03-312023-03-31

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2023

 

 

Tracon Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36818

34-2037594

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4350 La Jolla Village Drive, Suite 800

 

San Diego, California

 

92122

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 550-0780

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

TCON

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 1.01 Entry into a Material Definitive Agreement.

On April 5, 2023, TRACON Pharmaceuticals, Inc. (the “Company”) entered into a second amendment with effect from March 31, 2023 (the “Loan Amendment”) to the loan and security agreement, dated as of September 2, 2022 and amended December 22, 2022 (the “RGC Loan Agreement”), by and among the Company, each party to the RGC Loan Agreement from time to time a borrower thereunder, the lenders from time to time a party thereto and Runway Growth Finance Corp., as administrative agent and collateral agent for the lenders (“Lender”). The Loan Amendment amends the RGC Loan Agreement to, among other things, provide for the following terms: on or before April 15, 2023, if the Company has raised at least $25.0 million in net cash proceeds from certain equity or debt transactions prior to making such request, Lender may, in its sole and absolute discretion, allow or deny loaning to the Company an aggregate principal amount of $10.0 million, with the full amount funded in a single disbursement. If the loan described above is not made by April 15, 2023, the maturity date will be April 15, 2023, the RGC Loan Agreement will terminate on that date, and the Company will not be obligated to pay the prepayment fee described in the RGC Loan Agreement but the final payment fee described in the RCG Loan Agreement will become immediately due and payable.

All other material terms, including the interest-only period and covenants in the RGC Loan Agreement remain unchanged.

The foregoing summary of the material terms of the Loan Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Loan Amendment, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.

Forward-Looking Statements

Statements made in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, the availability of additional amounts under the RGC Loan Agreement. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with the Company’s ability to meet the conditions required to receive loans under the RGC Loan Agreement; clinical development and regulatory approval of novel pharmaceutical product candidates; whether the Company or others will be able to complete or initiate clinical trials on the Company’s expected timelines, if at all, including due to risks associated with the COVID-19 pandemic and macroeconomic events, such as the ongoing military conflict between Ukraine and Russia and related sanctions; recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures; the fact that the Company has limited control over whether or when third party collaborators complete on-going trials or initiate additional trials of the Company’s product candidates; whether the Company will be able to enter into additional collaboration agreements on favorable terms or at all; the Company’s reliance on third parties for the development of its product candidates, including the conduct of its clinical trials and manufacture of its product candidates; the results of the Company’s arbitration with I-Mab Biopharma, including whether the Company obtains an award in such arbitration; and other risks described in the Company’s filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TRACON Pharmaceuticals, Inc.

 

 

 

 

Date:

April 6, 2023

By:

/s/ Charles Theuer, M.D., Ph.D.

 

 

 

Charles Theuer, M.D., Ph.D.
President and Chief Executive Officer

 

 EX-101.SCH 2 tcon-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 tcon-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 tcon-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Mar. 31, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 31, 2023
Entity Registrant Name Tracon Pharmaceuticals, Inc.
Entity Central Index Key 0001394319
Entity Emerging Growth Company false
Securities Act File Number 001-36818
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 34-2037594
Entity Address, Address Line One 4350 La Jolla Village Drive, Suite 800
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (858)
Local Phone Number 550-0780
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TCON
Security Exchange Name NASDAQ
XML 6 tcon-20230331_htm.xml IDEA: XBRL DOCUMENT 0001394319 2023-03-31 2023-03-31 0001394319 false 8-K 2023-03-31 Tracon Pharmaceuticals, Inc. DE 001-36818 34-2037594 4350 La Jolla Village Drive, Suite 800 San Diego CA 92122 (858) 550-0780 false false false false Common Stock, par value $0.001 per share TCON NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tcon-20230331.htm tcon-20230331.xsd tcon-20230331_lab.xml tcon-20230331_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tcon-20230331.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tcon-20230331.htm" ] }, "labelLink": { "local": [ "tcon-20230331_lab.xml" ] }, "presentationLink": { "local": [ "tcon-20230331_pre.xml" ] }, "schema": { "local": [ "tcon-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tcon", "nsuri": "http://www.traconpharma.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tcon-20230331.htm", "contextRef": "C_dee1d148-8e49-46ec-a79a-5acecaa784bf", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tcon-20230331.htm", "contextRef": "C_dee1d148-8e49-46ec-a79a-5acecaa784bf", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.traconpharma.com/20230331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-012088-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-012088-xbrl.zip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end